Atea Pharmaceuticals, Inc.
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Jean-Pierre Sommadossi
- Full Time Employees
- 55
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 225 Franklin Street Boston MA United States of America 02110
- IPO Date
- Oct 30, 2020
- CIK
- 0001593899
- Website
- ateapharma.com
- Similar Companies
- Business
- Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical organization dedicated to the discovery, development, and commercialization of oral antiviral treatments for individuals facing severe viral infections. Leveraging a proprietary nucleos(t)ide prodrug platform, the company strategically advances novel therapeutic candidates, particularly targeting single-stranded ribonucleic acid (ssRNA) viruses, which are known causes of serious viral diseases. Currently, Atea’s primary focus centers on the advancement of a combination regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, for the treatment of hepatitis C virus (HCV). This regimen is progressing through a global Phase 3 development program, following positive Phase 2 results that demonstrated a 98% sustained virologic response at 12 weeks post-treatment with an eight-week duration. Atea secured exclusive worldwide rights to ruzasvir through a licensing agreement with Merck & Co. The company also maintains development efforts for bemnifosbuvir in the context of COVID-19, with a global Phase 3 trial (SUNRISE-3) having been initiated for high-risk non-hospitalized patients. Additionally, Atea has recently expanded its pipeline with a new development program targeting hepatitis E virus (HEV), specifically for immunocompromised patients. Earlier programs, such as AT-752 for dengue, were deprioritized in February 2023 to concentrate resources on the COVID-19 and HCV initiatives due to anticipated extensive clinical timelines and associated costs. Established in 2012, Atea Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.
Company News
BlackRock Inc. Makes New $40.55 Million Investment in Atea Pharmaceuticals, Inc. $AVIR
Atea Pharmaceuticals, Inc. (AVIR) Q2 2026 Earnings Call Transcript
Atea Pharmaceuticals Q2 Earnings Call Highlights
Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026
Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus
Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus
Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
Atea Pharmaceuticals (AVIR) Upgraded to Buy: Here's What You Should Know
Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year?
Atea Pharmaceuticals: I'm Optimistic Ahead Of Critical HPV Catalyst
Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026
Down 25% in 4 Weeks, Here's Why Atea Pharmaceuticals (AVIR) Looks Ripe for a Turnaround
Atea Pharmaceuticals to Present Three Abstracts at EASL 2026 Congress Highlighting Progress Across Viral Hepatitis Pipeline
Atea Pharmaceuticals, Inc. (AVIR) Q1 2026 Earnings Call Transcript
Atea Pharmaceuticals Q1 Earnings Call Highlights
Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
Atea Pharmaceuticals to Host First Quarter 2026 Financial Results and Business Update Conference Call on May 12, 2026
Atea Pharmaceuticals (NASDAQ:AVIR) vs. Trevi Therapeutics (NASDAQ:TRVI) Financial Survey
Atea Pharmaceuticals Q4 Earnings Call Highlights